1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Renzoni, D.A.
Pugh, D.J.R.
Siligardi, G.
Das, P.
Morton, C.J.
Rossi, C.
Waterfield, M.D.
Campbell, I.D.
Ladbury, J.E.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
35
15646
15653
10.1021/bi9620969
8961927
Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase.
1996
UK
Structure
STRUE6
2005
0969-2126
4
705
Solution Structure and Peptide Binding of the SH3 Domain from Human Fyn
1996
10.2210/pdb1azg/pdb
pdb_00001azg
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1405.640
PRO-PRO-ARG-PRO-LEU-PRO-VAL-ALA-PRO-GLY-SER-SER-LYS-THR
P85 SUBUNIT OF PI3-KINASE, RESIDUES 91 - 104
1
man
polymer
7554.108
FYN
2.7.1.112
SH3 DOMAIN, RESIDUES 82 - 148
N-TERMINAL GS FROM EXPRESSION SYSTEM
1
man
polymer
P2L
no
no
PPRPLPVAPGSSKT
PPRPLPVAPGSSKT
A
polypeptide(L)
no
no
TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEE
TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEE
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
Escherichia coli
sample
BL21
9606
Homo sapiens
469008
Escherichia coli BL21(DE3)
BL21 (DE3)
PGEX
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1998-02-25
1
1
2008-03-03
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
Y
BNL
1997-11-18
REL
50
1
REFINEMENT DETAILS CAN BE FOUND IN THE JRNL CITATION ABOVE.
BRUNGER
refinement
X-PLOR
3.1
PRO
91
n
1
PRO
91
A
PRO
92
n
2
PRO
92
A
ARG
93
n
3
ARG
93
A
PRO
94
n
4
PRO
94
A
LEU
95
n
5
LEU
95
A
PRO
96
n
6
PRO
96
A
VAL
97
n
7
VAL
97
A
ALA
98
n
8
ALA
98
A
PRO
99
n
9
PRO
99
A
GLY
100
n
10
GLY
100
A
SER
101
n
11
SER
101
A
SER
102
n
12
SER
102
A
LYS
103
n
13
LYS
103
A
THR
104
n
14
THR
104
A
n
1
82
B
n
2
83
B
VAL
84
n
3
VAL
84
B
THR
85
n
4
THR
85
B
LEU
86
n
5
LEU
86
B
PHE
87
n
6
PHE
87
B
VAL
88
n
7
VAL
88
B
ALA
89
n
8
ALA
89
B
LEU
90
n
9
LEU
90
B
TYR
91
n
10
TYR
91
B
ASP
92
n
11
ASP
92
B
TYR
93
n
12
TYR
93
B
GLU
94
n
13
GLU
94
B
ALA
95
n
14
ALA
95
B
ARG
96
n
15
ARG
96
B
THR
97
n
16
THR
97
B
GLU
98
n
17
GLU
98
B
ASP
99
n
18
ASP
99
B
ASP
100
n
19
ASP
100
B
LEU
101
n
20
LEU
101
B
SER
102
n
21
SER
102
B
PHE
103
n
22
PHE
103
B
HIS
104
n
23
HIS
104
B
LYS
105
n
24
LYS
105
B
GLY
106
n
25
GLY
106
B
GLU
107
n
26
GLU
107
B
LYS
108
n
27
LYS
108
B
PHE
109
n
28
PHE
109
B
GLN
110
n
29
GLN
110
B
ILE
111
n
30
ILE
111
B
LEU
112
n
31
LEU
112
B
ASN
113
n
32
ASN
113
B
SER
114
n
33
SER
114
B
SER
115
n
34
SER
115
B
GLU
116
n
35
GLU
116
B
GLY
117
n
36
GLY
117
B
ASP
118
n
37
ASP
118
B
TRP
119
n
38
TRP
119
B
TRP
120
n
39
TRP
120
B
GLU
121
n
40
GLU
121
B
ALA
122
n
41
ALA
122
B
ARG
123
n
42
ARG
123
B
SER
124
n
43
SER
124
B
LEU
125
n
44
LEU
125
B
THR
126
n
45
THR
126
B
THR
127
n
46
THR
127
B
GLY
128
n
47
GLY
128
B
GLU
129
n
48
GLU
129
B
THR
130
n
49
THR
130
B
GLY
131
n
50
GLY
131
B
TYR
132
n
51
TYR
132
B
ILE
133
n
52
ILE
133
B
PRO
134
n
53
PRO
134
B
SER
135
n
54
SER
135
B
ASN
136
n
55
ASN
136
B
TYR
137
n
56
TYR
137
B
VAL
138
n
57
VAL
138
B
ALA
139
n
58
ALA
139
B
PRO
140
n
59
PRO
140
B
VAL
141
n
60
VAL
141
B
n
61
142
B
n
62
143
B
n
63
144
B
n
64
145
B
n
65
146
B
n
66
147
B
n
67
148
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
B
O
PHE
109
B
O
PHE
28
B
N
PHE
87
B
N
PHE
6
B
N
VAL
88
B
N
VAL
7
B
O
ALA
139
B
O
ALA
58
B
O
ASN
113
B
O
ASN
32
B
N
GLU
121
B
N
GLU
40
B
N
TRP
120
B
N
TRP
39
B
O
ILE
133
B
O
ILE
52
1
B
THR
82
B
THR
1
1
Y
1
B
GLY
83
B
GLY
2
1
Y
1
B
ASP
142
B
ASP
61
1
Y
1
B
SER
143
B
SER
62
1
Y
1
B
ILE
144
B
ILE
63
1
Y
1
B
GLN
145
B
GLN
64
1
Y
1
B
ALA
146
B
ALA
65
1
Y
1
B
GLU
147
B
GLU
66
1
Y
1
B
GLU
148
B
GLU
67
1
Y
1
A
ARG
93
0.291
SIDE CHAIN
1
B
ARG
123
0.133
SIDE CHAIN
1
A
LEU
95
67.31
98.40
1
A
PRO
96
-61.17
98.10
1
A
ALA
98
-47.51
173.05
1
A
PRO
99
-60.78
83.30
1
B
THR
85
-152.64
71.58
1
B
ALA
95
-56.28
106.10
1
B
ASP
100
-64.57
-176.51
1
B
PHE
103
-174.58
-172.34
1
B
GLU
116
-57.23
-153.36
model building
X-PLOR
3.1
refinement
X-PLOR
3.1
phasing
X-PLOR
3.1
NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE KINASE COMPLEXED WITH THE SYNTHETIC PEPTIDE P2L CORRESPONDING TO RESIDUES 91-104 OF THE P85 SUBUNIT OF PI3-KINASE, MINIMIZED AVERAGE (PROBMAP) STRUCTURE
1
N
N
2
N
N
B
PRO
134
B
PRO
53
HELX_P
B
TYR
137
B
TYR
56
5
HA
4
COMPLEX (PHOSPHOTRANSFERASE/PEPTIDE)
COMPLEX (PHOSPHOTRANSFERASE-PEPTIDE), SH3 DOMAIN, POLYPROLINE-BINDING, PHOSPHOTRANSFERASE, COMPLEX (PHOSPHOTRANSFERASE-PEPTIDE) complex
P85A_HUMAN
UNP
1
1
P27986
MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRK
KISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAE
LRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTL
QYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANN
GMNNNMSLQNAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSS
VVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMK
RTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREID
KRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRG
KRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYA
QQRR
FYN_HUMAN
UNP
2
1
P06241
GCVQCKDKEATKLTEERDGSLNQSSGYRYGTDPTPQHYPSFGVTSIPNYNNFHAAGGQGLTVFGGVNSSSHTGTLRTRGG
TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEEWYFGKLGRKDAER
QLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAAGLCCR
LVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKTLKPGTMSPESFLEEAQIMKKL
KHDKLVQLYAVVSEEPIYIVTEYMNKGSLLDFLKDGEGRALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNG
LICKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELVTKGRVPYPGMNNREVLEQVER
GYRMPCPQDCPISLHELMIHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL
91
104
1AZG
91
104
P27986
A
1
1
14
81
147
1AZG
82
148
P06241
B
2
1
67
3
3
anti-parallel
anti-parallel
anti-parallel
anti-parallel
B
LYS
108
B
LYS
27
B
LEU
112
B
LEU
31
B
LEU
86
B
LEU
5
B
ALA
89
B
ALA
8
B
VAL
138
B
VAL
57
B
PRO
140
B
PRO
59
B
ASN
113
B
ASN
32
B
SER
114
B
SER
33
B
TRP
119
B
TRP
38
B
SER
124
B
SER
43
B
THR
130
B
THR
49
B
ILE
133
B
ILE
52
1
P 1